A SECRET WEAPON FOR SOTORASIB

FDA also authorized the FoundationOne®CDx assay being a companion diagnostic product to identify individuals with breast most cancers for treatment with capivasertib with fulvestrant.The invention and acceptance of sotorasib “opens up possibilities for creating compounds that bind to other mutant [KRAS] proteins,” Dr. McCormick said. G12C is a